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Abstract
Background: Few post-marketing surveillance studies have examined the safety and efficacy of Rapamune® (Sirolimus)
in Asian countries. This study aimed to better understand safety and efficacy of Rapamune for kidney transplant
recipients in the routine clinical practice setting in Korea.
Methods: This was an open-label, non-comparative, observational, prospective, multi-center, post-marketing
surveillance study conducted at 15 Korean transplant centers between 31 August 2009 and 24 September
2015. The subjects were administered Rapamune as part of routine practice. The safety was monitored based
on reporting of adverse events (AEs). Efficacy endpoints included acute rejection, graft function, graft survival,
and patient survival.
Results: Rapamune was most commonly used for late conversion therapy after post-transplant 1 year and
was substituted for anti-metabolites (63.6%) or calcineurin inhibitors (28.7%). The median treatment duration
of Rapamune was 182 days. Among 209 subjects enrolled, AEs and adverse drug reactions (ADRs) were reported in 54.
07% and 43.06% of subjects, respectively, in the safety analysis set. Most of the AEs were expected (96.21%), mild
(75.83%), did not result in any action taken with regard to the study drug (72.99%), and resolved by the end
of the study (75.36%). The most frequently reported AEs/ADRs were pharyngitis and diarrhea. Most of the serious
AEs/ADRs occurred in one or two subjects. Unexpected ADRs of renal artery occlusion and cholangitis were reported
by one subject each. The incidence of biopsy-proven acute rejection was 2.87%. At the end of the study, 99.51% of the
subjects and their grafts had survived. The mean eGFR was 64.72 ± 19.56 mL/min.
Conclusions: Rapamune had an acceptable safety profile in prevention of kidney allograft rejection in Korea.
Keywords: Kidney transplantation, Post-marketing surveillance, Sirolimus
Background
Rapamune® (Sirolimus) is a mammalian target of rapamycin
inhibitor. It is used as an immunosuppressive agent and is
effective in preventing acute rejection and in preserving
renal function in kidney transplant recipients [1, 2].
Rapamune is also used in either conversion or de novo reg-
imens [3, 4]. Rapamune administered at a dose of 1 mg was
approved for prophylaxis of organ rejection on 25 March
2006 in Korea. As required for any new medicine approved
by the Ministry of Food and Drug Safety (MFDS; previously
the Korea Food and Drug Administration), safety and effi-
cacy information of the medicine needed to be provided in
the routine practice setting during the re-examination
period of 6 years from the approval date (25 March 2006 to
24 March 2012) and the extended period (25 March 2012
to 24 September 2015). Two mg of Rapamune was
approved on 31 August 2009. Its safety and efficacy infor-
mation needed to be provided during the remaining
re-examination period of the 1 mg Rapamune dose.
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This non-interventional, prospective, post-marketing
surveillance study was designed to meet the requirement
of the MFDS. Otherwise, there were no benefit-risk is-
sues, safety concerns, or risk management measures that
led to the initiation or imposition of this study. Back-
ground information on Rapamune can be obtained from
the current version of the local product document (i.e.,
product label approved by the MFDS), which is the sin-
gle reference safety document for information relating to
Rapamune in this study.
Post-marketing surveillance is required to re-evaluate
risk and benefit issues associated with particular drugs
in the post-marketing environment because the safety
and efficacy of drugs in a clinical trial setting may not
coincide with those in clinical practice. The objective of
the present study was to analyze post-marketing surveil-
lance information to better understand safety and effi-
cacy of Rapamune for kidney transplant recipients in the
setting of routine clinical practice in Korea.
Methods
Study design and subjects
This was an open-label, non-comparative, observational,
prospective, multi-center study conducted at 15 centers
between 31 August 2009 and 24 September 2015. The
subjects were administered Rapamune as part of routine
practice at Korean transplantation centers by accredited
physicians or surgeons. The use and dosage recommen-
dations for Rapamune were based on the approved local
product document and were adjusted solely according to
medical and therapeutic necessity. Observation of sub-
jects was performed for 6 ± 1 months after initiating
Rapamune administration or until completion of Rapamune
administration, whichever was earlier. There were no
mandatory visits or activities during the study. The
investigator recorded the following information on
the subject’s case report form: demographic informa-
tion, subject status, transplantation status, general
medical history, prior immunosuppressive medication,
administration of Rapamune, concomitant medications
and therapies, trough level of immunosuppressive medica-
tions, and safety and efficacy information. Past medical
history was defined as any medical illness that had been
cured in the past and did not persist at the time of study
enrollment.
To be eligible for enrollment into the study, subjects
needed to be ≥13 years of age, renal transplant recipi-
ents, newly administered Rapamune after a contract was
made between Pfizer Korea and an investigator and/or
an institution for conducting this study, and to have pro-
vided personally signed and dated informed consent
document acknowledging having been informed of all
pertinent aspects of the study. For patients aged less
than 19 years, informed consent was obtained from both
patient and parents or guardians. Subjects presenting
with any of the following were excluded from the study:
(1) any subjects who did not agree with usage of his/her
information; (2) subjects with known hypersensitivity to
Rapamune or its derivatives, or any excipients in the for-
mulation; (3) subjects with hereditary problems such as
galactose intolerance, Lapp lactase deficiency, or glucose-
galactose malabsorption because Rapamune contains
lactose; and (4) any reproductive aged woman with a
birth plan.
This study was approved by the Institutional Review
Board of each participating center, and it was performed
in accordance with the Helsinki Declaration of 2000 and
the Declaration of Istanbul 2008.
Outcome measurement
Safety was monitored throughout the observation
period. An adverse event (AE) was defined as any unto-
ward medical occurrence including symptom, sign, and
disease in a subject administered Rapamune. The event
did not need to have a causal relationship with the prod-
uct or usage. AE recording included identification of the
AE, onset and resolution dates, severity, action taken
with Rapamune, seriousness, outcome, and causality
assessment (certain, probable/likely, possible, unlikely,
conditional/unclassified, unassessable/unclassifiable). For
all AEs, sufficient information should have been ob-
tained by the investigator to determine the causality of
each AE. For AEs with a causal relationship to Rapa-
mune, follow-up by the investigator was required until
the event or its sequelae resolved or stabilized at a level
acceptable to the investigator. The investigators decided
the medical term of AEs clinically, and all AEs were
standardized and classified based on systemic organ class
and preferred term according to the World Health
Organization Adverse Reaction Terminology, version
092. A serious AE (SAE) was defined as any untoward
medical occurrence in a subject administered a medicinal
product any dose that: (1) resulted in death, (2) was
life-threatening, (3) required inpatient hospitalization or
prolongation of hospitalization, (4) resulted in persistent
or significant disability/incapacity, or (5) resulted in con-
genital anomaly or birth defect. All AEs, except for those
for which a causal relationship to the study drug was “un-
likely”, were considered as adverse drug reactions (ADRs)
in this study.
The efficacy endpoints included incidence rate of biop-
sy-confirmed acute rejection using Banff 09 diagnostic cat-
egories for renal allograft biopsies, graft function, patient
survival, and graft survival. Graft function was evaluated
by estimated glomerular filtration rate (eGFR) using the
Nankivell formula calculated with the following equation:
GFR (mL/min) = 6.7/creatinine (mmol/L) – urea (mmol/
L)/2 + body weight (kg)/4–100/height (m)2 + (35 [male] or
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25 [female]). The Nankivell equation is one of the most
accurate methods of the creatinine-based estimates for
eGFR in kidney transplant recipients [5, 6]. Graft loss was
defined as the initiation of dialysis, graft nephrectomy,
re-transplantation, or patient death with a functioning
graft.
Sample size determination
No formal sample size calculation was performed in this
observational study. At least 600 subjects were to be en-
rolled in this study based on the requirement of the
MFDS. However, considering the difficulty of subject en-
rollment, the MFDS extended the re-examination period
and adjusted the number of subjects. Therefore, the
planned enrollment was at least 200 subjects during
the re-examination period and the extended period in
this study.
Statistical analyses
Descriptive summary statistics for continuous variables
included number of subjects, mean, median, standard
deviation, minimum, and maximum. Descriptive statis-
tics for categorical variables were given as frequencies
and percentages. The proportion of subjects who experi-
enced AEs were estimated and compared among subcat-
egories of each baseline and treatment characteristic
using the chi-square test or Fisher’s exact test. The pro-
portion of subjects who had survived and whose graft
had survived at the time of final evaluation was calcu-
lated with its 95% confidence interval estimated for ana-
lysis of patient and graft survival. All statistical analyses
were carried out with statistical analysis system (SAS)
software versions 9.3 and 9.4. All test statistics were
based on 2-sided tests with the statistical significance
level of 0.05.
Results
Patient demographics and baseline characteristics
A total of 209 kidney transplant recipients who were
treated with Rapamune were enrolled. All subjects were
included in both the safety analysis set and the efficacy
analysis set. The baseline demographics and clinical
characteristics of subjects in this study are summarized
in Table 1. The mean age was 47.93 ± 13.10 years and
61.24% of the subjects were male. The majority of sub-
jects (87.56%) were under 65 years of age. The most
common cause of primary kidney failure was hyperten-
sion followed by glomerulonephritis, diabetes mellitus,
and polycystic kidney disease. Median number of HLA
mismatch was 3.00 (range: 0 to 6). Among 208 subjects
who had type of donor data, 132 (63.46%) subjects under-
went living donor kidney transplantation, and the mean
age of donors was 41.49 ± 13.16 years. Mean positive class
I and class II panel reactive antibodies were 6.35 ± 21.50%
and 5.89 ± 17.39%, respectively (Table 1).
Immunosuppressive medications
All 209 subjects took concomitant immunosuppressive
medications during the study, and most subjects (78.95%)
took two or more concomitant immunosuppressive medi-
cations. The most common concomitant immunosuppres-
sants were a dual combination of calcineurin inhibitor and
steroid (41.15%). Rapamune was substituted for other im-
munosuppressants (85.4%) or was added on other immu-
nosuppressants (14.6%). Among the conversion group,
anti-metabolites were converted to Rapamune most fre-
quently (63.6%) and calcineurin inhibitors were converted
to Rapamune in 28.7%.
The median time from kidney transplantation to the
first administration of Rapamune was 909 days (range: 9
to 10,816 days). Rapamune was introduced in 28 sub-
jects (13.40%) within 6 months; however, most subjects
(159 subjects, 76.08%) began to take Rapamune 1 year
after transplantation (Table 1). Calcineurin inhibitors
were also converted to Rapamune within 6 months only
in 13.51% and conversion occurred after 1 year in most
cases (75.7%).
The median administration period of Rapamune was
182 days (range: 4 to 971 days). The mean daily dose of
Rapamune is 1.79 ± 0.68 mg/day, and more than half of
the subjects (53.59%) were treated with daily dose of <
2 mg/day. The mean trough level of Rapamune was 5.45
± 2.59 ng/mL as measured using immunoassay and 7.87
± 4.24 ng/mL as determined using high performance li-
quid chromatography (HPLC). The mean trough level of
concomitant tacrolimus was 4.34 ± 1.77 ng/mL and 4.51
± 3.25 ng/mL as determined using immunoassay and
HPLC, respectively. The mean trough level of concomi-
tant cyclosporine was 72.84 ± 47.01 ng/mL and 100.18 ±
64.80 ng/mL in the same respective order (Table 1).
Safety
At the time of study completion, 3 subjects were lost to
follow up in our study, and 206 subjects were evaluated
in the safety analysis set. Among 206 subjects, 167
(79.9%) were continuing Rapamune administration and
39 (18.66%) discontinued the treatment. Discontinuation
was because of AEs in 87.18% (34/39) of the subjects
and for other reasons in 10.26% (4/39). The other rea-
sons included elevation of serum creatinine, subjective
refusal, informed consent withdrawal, and cecal tubercu-
losis. Another subject discontinued due to AEs and was
switched from Rapamune to mycophenolic acid. Four
subjects restarted Rapamune, but 35 subjects perman-
ently discontinued Rapamune due to AEs. The most
commonly reported AEs that led to discontinuation were
azotemia in 6 subjects and diarrhea in 5 subjects.
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The list of AEs that lead to discontinuation of Rapa-
mune is summarized in Table 2.
All AEs and ADRs that occurred during the study are
summarized in Table 3. Overall, 113 (54.07%) subjects
experienced 211 AEs. The majority of AEs were ex-
pected (96.21%), non-serious (86.73%), mild (75.83%),
did not result in any action taken with regard to the
study drug (72.99%), and resolved by the end of the
study (75.36%). AEs occurred most frequently in resist-
ance mechanism disorders (48, 22.97%) and gastro-intes-
tinal system disorders (39, 18.66%). The most frequently
reported AEs by preferred term were pharyngitis (24,
11.48%) and diarrhea (12, 5.74%). Almost all AEs were
mild (75.83%, 160/211) or moderate (20.38%, 43/211).
AEs of severe intensity were reported in 3.79% (8/
211) of subjects.
The proportion of subjects with AEs within each cat-
egory of predefined baseline and clinical characteristic
was compared using chi-square test or Fisher’s exact
test. There were statistically significant differences in
proportion of subjects with AEs across subgroups in the
following categories. The subjects with the time between
transplantation and first administration of Rapamune in
less than 1 year had more AEs than those in 1 to 5 years
or in longer than 5 years (70.21% vs. 48.42% vs. 52.31%
respectively, P = 0.0445). More AEs were evident for sub-
jects who had a past medical history compared to those
without such history (60.28% vs. 41.18%, P = 0.0094),
and subjects who had liver disease compared to those
without liver disease (92.31% vs. 51.53%, P = 0.0043).
Table 1 Clinical characteristics of study subjects
Total (N = 209)
Age, years 47.93 ± 13.10
Age group, n (%)
< 65 years 183 (87.56)
≥ 65 years 26 (12.44)
Sex, male, n (%) 128 (61.24)
Height, cm 164.85 ± 8.80
Body Weight, kg 61.73 ± 10.75
Allergy history, n (%) 5 (2.39)
Secondary transplantation, n (%) 10 (4.78%)
Primary cause of kidney failure, n (%)
Hypertension 56 (26.79)
Diabetes mellitus 33 (15.79)
Glomerulonephritis 55 (26.32)
Polycystic kidney disease 11 (5.26)
Others 54 (25.84)
Panel reactive antibody of recipients (%)
Class I 6.35 ± 21.50
Class II 5.89 ± 17.39
Type of donation, n (%)
Living donor 132 (63.46)
Deceased donor 76 (36.54)
Age of donors, years 41.49 ± 13.16
Past general medical history, n (%)a 141 (67.46%)
Liver disease, n (%) 13 (6.22%)
Concomitant immunosuppressive medication, n (%)b
Monotherapy 44 (21.05)
Dual therapy 140 (66.99)
Triple therapy 25 (11.96)
Trough level of cyclosporine, ng/mL
Immunoassay 72.84 ± 47.01
HPLC method 100.18 ± 64.80
Trough level of tacrolimus, ng/mL
Immunoassay 4.34 ± 1.77
HPLC method 4.51 ± 3.25
Trough level of mycophenolic acid, ng/mL
HPLC method 1.53 ± 0.86
Time between transplantation and the
first administration of Rapamune, days,
median (range)
median 909
(range: 9 to 10,816)
< 6 months, n (%) 28 (13.40)
6 months to < 1 year, n (%) 20 (9.57)
1 year to < 5 years, n (%) 94 (44.98)
≥ 5 years, n (%) 65 (31.10)
Table 1 Clinical characteristics of study subjects (Continued)
Total (N = 209)
Total administration period of Rapamune, days median 182
(range: 4 to 971)
< 6 months, n (%) 96 (45.93)
6 month to < 1 year, n (%) 99 (47.37)
≥ 1 year, n (%) 14 (6.70)
Daily dose of Rapamune, mg 1.79 ± 0.68
< 2 mg, n (%) 112 (53.59)
2 mg, n (%) 46 (22.01)
> 2 mg, n (%) 51 (24.40)
Trough level of Rapamune, ng/mL
Immunoassay 5.45 ± 2.59
HPLC method 7.87 ± 4.24
Most numerical values are presented as a mean ± standard deviation, and
categorical values are expressed as a frequency (percentage)
Abbreviations: cm centimeter(s), kg kilogram(s), HPLC high performance
liquid chromatography
aPast general medical history was defined as any medical illness that had been
cured in the past and did not persist at the time of study enrollment
bMonotherapy: steroid only, calcineurin inhibitor only, or anti-metabolite only;
Dual therapy: steroid plus calcineurin inhibitor, steroid plus anti-metabolite, or
calcineurin inhibitor plus anti-metabolite; Triple therapy: steroid plus calcineurin
inhibitor plus anti-metabolite
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AEs were significantly different according to the total
administration duration of Rapamune, with rates of
69.79% for < 6 months, 45.45% for 6 months to 1 year,
and 7.14% for ≥1 year (P < 0.0001). Subjects continuously
administered Rapamune at the time of study completion
had significantly less AEs than those who had discontin-
ued Rapamune (44.31% vs. 92.31%, P < 0.0001).
Among 211 AEs from 113 subjects, 156 AEs (73.9%)
from 90 subjects were considered as ADRs according to
the causality assessment of the investigator (conditional/
unclassified: 41.71%; possible: 21.33%; probable/likely:
4.74%; certain: 4.74%; unassessable/unclassifiable: 1.42%).
ADRs occurred most frequently in the systemic organ
class of resistance mechanism disorders (35, 16.75%) and
gastro-intestinal system disorders (34, 16.27%). The most
frequently reported ADRs by preferred term were pharyn-
gitis (23, 11.00%) and diarrhea (11, 5.26%). Other ADRs
that reported in ≥1% of subjects included stomatitis, sto-
matitis ulcerative, azotemia (each reported by 7 subjects,
3.35% each), upper respiratory tract infection, acne (each
reported by 5 subjects, 2.39% each), abdominal pain, rash
(each reported by 4 subjects, 1.91% each), diabetes melli-
tus, transplant rejection, and coughing (each reported by
3 subjects, 1.44% each). Seven (3.35%) subjects experi-
enced 8 unexpected AEs during the study, of which 2
(0.96%) subjects experienced 2 unexpected ADRs (renal
artery occlusion and cholangitis in 1 subject, 0.48% each).
The one death involved a 78-year-old male subject who
had a medical history of liver disease. He died on Study
Day 61 due to a SAE (acute cholangitis), which was con-
sidered to be possibly related to the study drug by the
investigator.
All SAEs/serious adverse drug reactions (SADRs) by
World Health Organization Adverse Reaction Terminology
systemic organ class and preferred term are summarized in
Table 4 for the safety analysis set. A total of 16 subjects
(7.66%) experienced 28 SAEs during the study. All SAEs
were reported in 1 or 2 subjects except for azotemia, which
was reported in 4 (1.91%) subjects. Six (2.87%) sub-
jects experienced 9 SADRs, which were azotemia (3,
1.44%), diarrhea (2, 0.96%), pneumonia, increased in-
fection susceptibility, herpes zoster, and cholangitis
(each reported by 1 subject, 0.48% each). A total of 5
(2.39%) subjects reported 5 unexpected SAEs; 1 (0.48%)
subject reported 1 unexpected SADR; the cholangitis
was fatal.
Efficacy
Efficacy data for biopsy-confirmed acute rejection, pa-
tient survival, graft survival, and graft function evaluated
by eGFR are summarized in Table 5. In the efficacy ana-
lysis set, 6 subjects had biopsy-confirmed acute rejection
using Banff 09 diagnostic categories for renal allograft
biopsies. The incidence of acute rejection was 2.87%.
None of 6 subjects who were diagnosed as acute rejec-
tion had donor specific anti-HLA antibodies, and either
acute or chronic antibody-mediated rejection was not










Infection susceptibility increased 1 (0.48) 1
Polyomavirus infection 1 (0.48) 1
Gastro-intestinal system disorders
Diarrhoea 5 (2.39) 5
Stomatitis 3 (1.44) 3
Stomatitis ulcerative 1 (0.48) 1
Abdominal pain 2 (0.96) 2
Nausea 1 (0.48) 1
Urinary system disorders
Azotaemia 6 (2.87) 6
Albuminuria 1 (0.48) 1
Oliguria 1 (0.48) 1
Skin and appendages disorders
Acne 1 (0.48) 1
Rash 1 (0.48) 1
Rash erythematous 2 (0.96) 2
Dermatitis 1 (0.48) 1
Metabolic and nutritional disorders
Diabetes mellitus 1 (0.48) 1
Diabetes mellitus aggravated 1 (0.48) 1
Plasma osmolality increased 1 (0.48) 1
Body as a whole– general disorders
Edema peripheral 1 (0.48) 1
Face edema 2 (0.96) 2
Anaphylactic reaction 1 (0.48) 1
Liver and biliary system disorders
Hepatic function abnormal 1 (0.48) 1
Cholangitis 1 (0.48) 1
Musculo-skeletal system disorders
Avascular necrosis bone 1 (0.48) 1
Secondary terms – events
Transplant rejection 2 (0.96) 2
Respiratory system disorders
Coughing (≥ 4 weeks) 1 (0.48) 1
White cell and RES disorders
Leucopenia 1 (0.48) 1
aAdverse drug reactions classified according to the World Health Organization
Adverse Reaction Terminology (WHO-ART) version 092 coding dictionary
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Table 3 Adverse events and adverse drug reactions classified by systemic organ class according to the World Health Organization
Adverse Reaction Terminology
Systemic organ class and preferred terma Total (N = 209)
Adverse Event Adverse Drug Reaction
Number of Subjects (%) Number of Events Number of Subjects (%) Number of Events
Total 113 (54.07) 211 90 (43.06) 156
Resistance mechanism disorders 48 (22.97) 66 35 (16.75) 50
Pharyngitis 24 (11.48) 32 23 (11.00) 31
Upper respiratory tract infection 10 (4.78) 15 5 (2.39) 10
Urinary tract infection 4 (1.91) 4 1 (0.48) 1
Rhinitis 3 (1.44) 3 0 (0.00) 0
Pneumonia 3 (1.44) 3 2 (0.96) 2
Herpes simplex 2 (0.96) 2 2 (0.96) 2
Cystitis 2 (0.96) 2 1 (0.48) 1
Infection susceptibility increased 1 (0.48) 1 1 (0.48) 1
Abscess 1 (0.48) 1 0 (0.00) 0
Herpes zoster 1 (0.48) 1 1 (0.48) 1
Dermatitis fungal 1 (0.48) 1 1 (0.48) 1
Polyomavirus infection 1 (0.48) 1 0 (0.00) 0
Gastro-intestinal system disorders 39 (18.66) 49 34 (16.27) 38
Diarrhoea 12 (5.74) 13 11 (5.26) 11
Stomatitis 7 (3.35) 7 7 (3.35) 7
Stomatitis ulcerative 7 (3.35) 7 7 (3.35) 7
Abdominal pain 4 (1.91) 4 4 (1.91) 4
Gastritis 3 (1.44) 3 2 (0.96) 2
Constipation 2 (0.96) 2 1 (0.48) 1
Dyspepsia 2 (0.96) 3 2 (0.96) 3
Nausea 2 (0.96) 2 1 (0.48) 1
Enteritis 2 (0.96) 2 1 (0.48) 1
Vomiting 1 (0.48) 2 0 (0.00) 0
Ileus 1 (0.48) 2 0 (0.00) 0
Tooth caries 1 (0.48) 1 0 (0.00) 0
Periodontal destruction 1 (0.48) 1 1 (0.48) 1
Urinary system disorders 15 (7.18) 16 11 (5.26) 11
Azotaemia 10 (4.78) 10 7 (3.35) 7
Albuminuria 2 (0.96) 2 2 (0.96) 2
Nephropathy toxic 1 (0.48) 1 0 (0.00) 0
Urinary tract disorder 1 (0.48) 1 0 (0.00) 0
Oliguria 1 (0.48) 1 1 (0.48) 1
Renal artery occlusion 1 (0.48) 1 1 (0.48) 1
Skin and appendages disorders 15 (7.18) 17 13 (6.22) 14
Acne 5 (2.39) 5 5 (2.39) 5
Rash 4 (1.91) 4 4 (1.91) 4
Onychomycosis 2 (0.96) 2 1 (0.48) 1
Rash erythematous 2 (0.96) 2 2 (0.96) 2
Folliculitis 1 (0.48) 1 0 (0.00) 0
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Table 3 Adverse events and adverse drug reactions classified by systemic organ class according to the World Health Organization
Adverse Reaction Terminology (Continued)
Systemic organ class and preferred terma Total (N = 209)
Adverse Event Adverse Drug Reaction
Number of Subjects (%) Number of Events Number of Subjects (%) Number of Events
Eczema 1 (0.48) 1 1 (0.48) 1
Dermatitis contact 1 (0.48) 1 0 (0.00) 0
Dermatitis 1 (0.48) 1 1 (0.48) 1
Metabolic and nutritional disorders 13 (6.22) 14 11 (5.26) 12
Diabetes mellitus 3 (1.44) 3 3 (1.44) 3
Hyperlipemia 4 (1.91) 4 4 (1.91) 4
Hyperkalemia 2 (0.96) 2 2 (0.96) 2
Diabetes mellitus aggravated 2 (0.96) 2 2 (0.96) 2
Hyperphosphatemia 1 (0.48) 1 0 (0.00) 0
Glycosuria 1 (0.48) 1 1 (0.48) 1
Plasma osmolality increased 1 (0.48) 1 0 (0.00) 0
Body as a whole– general disorders 11 (5.26) 11 8 (3.83) 8
Edema peripheral 2 (0.96) 2 2 (0.96) 2
Face edema 2 (0.96) 2 2 (0.96) 2
Fever 2 (0.96) 2 1 (0.48) 1
Allergic reaction 1 (0.48) 1 1 (0.48) 1
Leg pain 1 (0.48) 1 0 (0.00) 0
Ascites 1 (0.48) 1 0 (0.00) 0
Anaphylactic reaction 1 (0.48) 1 1 (0.48) 1
Fatigue 1 (0.48) 1 1 (0.48) 1
Liver and biliary system disorders 6 (2.87) 7 3 (1.44) 4
SGOT increased 2 (0.96) 2 1 (0.48) 1
Hepatic enzymes increased 2 (0.96) 2 0 (0.00) 0
SGPT increased 1 (0.48) 1 1 (0.48) 1
Hepatic function abnormal 1 (0.48) 1 1 (0.48) 1
Cholangitis 1 (0.48) 1 1 (0.48) 1
Musculo-skeletal system disorders 6 (2.87) 6 4 (1.91) 4
Osteoporosis 2 (0.96) 2 2 (0.96) 2
Fracture 2 (0.96) 2 0 (0.00) 0
Myalgia 1 (0.48) 1 1 (0.48) 1
Avascular necrosis bone 1 (0.48) 1 1 (0.48) 1
Secondary terms – events 6 (2.87) 6 3 (1.44) 3
Transplant rejection 6 (2.87) 6 3 (1.44) 3
Respiratory system disorders 4 (1.91) 4 3 (1.44) 3
Coughing 3 (1.44) 3 3 (1.44) 3
Dysonoea 1 (0.48) 1 0 (0.00) 0
White cell and RES disorders 3 (1.44) 3 2 (0.96) 2
Leucopenia 2 (0.96) 2 2 (0.96) 2
Granulocyopenia 1 (0.48) 1 0 (0.00) 0
Central & peripheral nervous system disorders 3 (1.44) 4 2 (0.96) 3
Headache 2 (0.96) 2 1 (0.48) 1
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found in their biopsy results. Among 6 subjects who had
acute rejection episodes, 5 patients had begun to take
Rapamune within the first year after transplantation. In
their biopsy results, 3 subjects had borderline change, 2
subjects had acute T cell mediated rejection type IA, and
1 subject had acute T cell mediated rejection type IB.
Among them, 4 subjects received steroid pulse therapy
except 2 subjects who had borderline change. Five sub-
jects recovered their graft function, however, graft failure
occurred in 1 subject who had acute T cell mediated re-
jection type IB after study completion. Among 206 sub-
jects who had patient survival data, 205 subjects
survived at the time of final evaluation. The survival rate
was 99.51%. Among 206 subjects who had graft survival
data, 205 subjects had no graft loss at the time of final
evaluation. The proportion of subjects with a surviving
graft was 99.51% at a median follow-up of 182 days. The
median and mean eGFR calculated by Nankivell formula
was 67.07 mL/min (range: 4.80 to 113.27 mL/min) and
64.72 ± 19.56 mL/min, respectively for the 182 subjects
who had graft function data in the efficacy analysis set.
Discussion
Post-marketing surveillance studies can reveal hitherto
unknown or unexpected safety issues, providing clini-
cians with valuable information about the drugs. The
present study was a non-interventional study of the
safety and efficacy of Rapamune used in routine clinical
practice in Korean kidney transplant recipients. Rapa-
mune was most commonly used for late conversion
therapy after post-transplant 1 year and was substituted
for anti-metabolites (63.6%) or calcineurin inhibitors
(28.7%). Most of the AEs were expected, mild, and
self-limiting. Furthermore, these AEs might not be at-
tributed to Rapamune as there was no control group.
Kidney allograft rejection rate was low with good renal
function and graft survival at short-term follow-up.
Overall, we demonstrated the acceptable tolerability of
Rapamune in Korean kidney transplant recipients in
routine clinical environment.
Importantly, the cumulative incidence of AEs (54.07%)
was lower than that reported in previous randomized
controlled trials [7–9]. The previous studies reported
that almost all subjects treated with sirolimus had at
least one AE [7–9]. Furthermore, 16.75% of subjects per-
manently discontinued Rapamune due to AEs in this
study, whereas AEs led to discontinuation of study drug
in 21–23% of subjects in the clinical trials [8, 9]. These
differences between clinical trials and post-marketing
surveillance study could be explained by the more strin-
gent protocols of randomized controlled trials. In this
observational, non-interventional study, clinicians could
Table 3 Adverse events and adverse drug reactions classified by systemic organ class according to the World Health Organization
Adverse Reaction Terminology (Continued)
Systemic organ class and preferred terma Total (N = 209)
Adverse Event Adverse Drug Reaction
Number of Subjects (%) Number of Events Number of Subjects (%) Number of Events
Hypoaesthesia 1 (0.48) 1 1 (0.48) 1
Tremor 1 (0.48) 1 1 (0.48) 1
Red blood cell disorders 2 (0.96) 2 2 (0.96) 2
Anaemia 1 (0.48) 1 1 (0.48) 1
Polycythaemia 1 (0.48) 1 1 (0.48) 1
Endocrine disorders 1 (0.48) 1 0 (0.00) 0
Hyperparathyroidism 1 (0.48) 1 0 (0.00) 0
Vision disorders 1 (0.48) 1 1 (0.48) 1
Meibomianitis 1 (0.48) 1 1 (0.48) 1
Myo-, endo-, pericardial & valve disorders 1 (0.48) 1 0 (0.00) 0
Angina pectoris aggravated 1 (0.48) 1 0 (0.00) 0
Cardiovascular disorders, general 1 (0.48) 1 0 (0.00) 0
Hypertension 1 (0.48) 1 0 (0.00) 0
Psychiatric disorders 1 (0.48) 1 1 (0.48) 1
Insomnia 1 (0.48) 1 1 (0.48) 1
Platelet, bleeding & clotting disorders 1 (0.48) 1 0 (0.00) 0
Thrombocytopenia 1 (0.48) 1 0 (0.00) 0
Abbreviations: RES reticuloendothelial system
aAdverse drug reactions classified according to the World Health Organization Adverse Reaction Terminology (WHO-ART) version 092 coding dictionary
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select the optimal dose of Rapamune according to the
response of each patient in terms of the balance between
benefit and risk. However, in the clinical trials, study
drug dose and method of administration was determined
according to the strict protocol of the trials. Euvrard
et al. [9] reported that subjects who were converted to
sirolimus with rapid protocols had a higher rate of dis-
continuation as well as a higher incidence of SAEs than
Table 4 Serious adverse events and serious adverse drug reactions classified by systemic organ class according to the World Health
Organization Adverse Reaction Terminology
Systemic organ class and preferred terma Total (N = 209)
SAEs SADRs
Number of Subjects (%) Number of Events Number of Subjects (%) Number of Events
Total 16 (7.66) 28 6 (2.87) 9
Resistance mechanism disorders 6 (2.87) 7 3 (1.44) 3
Pneumonia 2 (0.96) 2 1 (0.48) 1
Cystitis 1 (0.48) 1 0 (0.00) 0
Infection susceptibility increased 1 (0.48) 1 1 (0.48) 1
Abscess 1 (0.48) 1 0 (0.00) 0
Herpes zoster 1 (0.48) 1 1 (0.48) 1
Polyomavirus infection 1 (0.48) 1 0 (0.00) 0
Gastro-intestinal system disorders 3 (1.44) 4 2 (0.96) 2
Diarrhea 2 (0.96) 2 2 (0.96) 2
Ileus 1 (0.48) 2 0 (0.00) 0
Urinary system disorders 5 (2.39) 5 3 (1.44) 3
Azotemia 4 (1.91) 4 3 (1.44) 3
Urinary tract disorder 1 (0.48) 1 0 (0.00) 0
Skin and appendages disorders 1 (0.48) 1 0 (0.00) 0
Dermatitis contact 1 (0.48) 1 0 (0.00) 0
Metabolic and nutritional disorders 1 (0.48) 1 0 (0.00) 0
Plasma osmolality increased 1 (0.48) 1 0 (0.00) 0
Body as a whole– general disorders 1 (0.48) 1 0 (0.00) 0
Ascites 1 (0.48) 1 0 (0.00) 0
Liver and biliary system disorders 1 (0.48) 1 1 (0.48) 1
Cholangitis 1 (0.48) 1 1 (0.48) 1
Musculo-skeletal system disorders 1 (0.48) 1 0 (0.00) 0
Fracture 1 (0.48) 1 0 (0.00) 0
Secondary terms – events 2 (0.96) 2 0 (0.00) 0
Transplant rejection 2 (0.96) 2 0 (0.00) 0
Respiratory system disorders 1 (0.48) 1 0 (0.00) 0
Dyspnea 1 (0.48) 1 0 (0.00) 0
White cell and RES disorders 1 (0.48) 1 0 (0.00) 0
Granulocyopenia 1 (0.48) 1 0 (0.00) 0
Endocrine disorders 1 (0.48) 1 0 (0.00) 0
Hyperparathyroidism 1 (0.48) 1 0 (0.00) 0
Myo-, endo-, pericardial & valve disorders 1 (0.48) 1 0 (0.00) 0
Angina pectoris aggravated 1 (0.48) 1 0 (0.00) 0
Cardiovascular disorders, general 1 (0.48) 1 0 (0.00) 0
Hypertension 1 (0.48) 1 0 (0.00) 0
Abbreviations: RES reticuloendothelial system, SAEs serious adverse events, SADRs serious adverse drug reactions
aAdverse drug reactions classified according to the World Health Organization Adverse Reaction Terminology (WHO-ART) version 092 coding dictionary
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those with progressive protocols. While the target
trough level of sirolimus in the clinical trials were 5–
15 ng/mL, the mean trough level reported here was 5.45
± 2.59 ng/mL and most of the subjects had daily dose of
Rapamune of 2 mg (22.01%) or less than 2 mg (53.59%)
in the present study. Lower trough concentrations
with gradual dose adjustment in the real clinical prac-
tice could have resulted in better safety profile in the
present study.
Presently, the most common AEs were resistance
mechanism disorders including pharyngitis and gastro-
intestinal system disorders such as diarrhea. These
findings were consistent with previous studies [7–9].
However, most studies commonly reported acne, dyslip-
idemia, mouth ulceration, peripheral edema, and pro-
teinuria with sirolimus use [7–9]. Relatively few subjects
experienced these AEs in the present study, and this
might be also explained by the aforementioned reasons.
Additionally, our study showed that the subjects with
the time between transplantation and first administra-
tion of Rapamune in less than 1 year had significantly
more AEs than those in longer than 1 year. Obviously,
most AEs in the Rapamune use are concentration-related.
Doses and levels obtained during the first year after trans-
plantation may differ from those in longer than 1 year
could have contributed to the significantly different inci-
dence of AEs between the two groups.
At the end of the study, patient survival and graft
survival rates were 99.51%. Graft failure occurred in
1 case and the cause of graft failure was death with
a functioning graft from cholangitis. The incidence
of biopsy-proven acute rejection was 2.87% and
eGFR (mean 64.72 ± 19.56 mL/min) was remained
stable in this study. These results are consistent with
previous studies that investigated the efficacy of siro-
limus [1, 2, 8, 10, 11]. Even though treatment dur-
ation of Rapamune in this study was relatively short
(median treatment duration: 182 days; range: 4 to
971 days), these findings indicated that Rapamune
was effective in prevention of kidney allograft rejec-
tion and in preserving renal function especially in
kidney transplant subjects who had begun to take
Rapamune 1 year after transplantation.
The present study has some limitations. First, this
study was an observational post-marketing surveillance
study to satisfy the requirements of the MFDS. The
protocol and statistical analysis plan were determined by
regulation of the MFDS rather than characteristics of
specific disease or drug. The non-interventional, non-
comparative, and non-randomized design of this study is
an intrinsic limitation. However, the observational design
of this study is more likely to provide information re-
lated to routine clinical practice compared to random-
ized controlled trials. Second, the treatment duration of
Rapamune was relatively short (median: 182 days), and
the time from kidney transplantation to the first dose of
Rapamune was heterogenous (median: 909 days; range: 9
to 10,816 days). However, most AEs occurred in the
early period after initiation of Rapamune, and the majority
of subjects (77.29%) received the first dose of Rapamune
later than 1 year after kidney transplantation. Third, the
study population was relatively small. Large-scale, long-
term studies would be helpful. Nevertheless, the present
study is meaningful as it provides important information
about safety and efficacy of Rapamune in routine clinical
practice for Asian kidney transplant subjects; most of the
prior studies have been performed with Caucasians.
Conclusions
Rapamune had an acceptable safety profile in prevention
of kidney allograft rejection in Korea. The study results
had no impact on the known benefit-risk balance of
Rapamune.
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